Autoimmune diseases are becoming a global health problem and can be chronic and life-threatening. Statistics show that around 50 Mn in the U.S. itself suffer from autoimmune diseases.
This makes it all the more imperative to fast track their cure. Biocon is pioneering targeted therapies and exploring potential treatments to transform the breakdown of the body’s immunity into a breakthrough medical innovation
Novel Biologics
ITOLIZUMAB
Itolizumab is the first novel, humanised anti-CD6 monoclonal antibody to be approved anywhere in the world. It was launched in India in 2013 under the brand name ALZUMAb™, to treat moderate to severe plaque psoriasis.
Itolizumab is the second novel biologic drug that Biocon has taken from ‘lab to market’. It has been out licensed to U.S.-based Equillium, which plans to develop and commercialise the drug in the U.S., Canada, Australia and New Zealand.
Equillium is currently studying Itolizumab under two open U.S. INDs for the treatment of acute graft-versus-host disease (aGVHD) and lupus nephritis, as well as conducting an additional clinical study in uncontrolled asthma in Australia and New Zealand.
Immunosuppressants
Biocon is one of the world’s largest producers of Immunosuppressants
As one of the world’s largest producers of immunosuppressants, Biocon leverages its comprehensive portfolio of topical, systemic and biologic therapies to treat immune-mediated skin diseases like psoriasis, atopic dermatitis and vitiligo.
Biocon has a full suite of generic immunosuppressants that include:
You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.
